Sunshine Lake Pharma Co., Ltd.

This study tested a combination of two drugs (ningetinib and gefitinib) in 108 people with advanced non-small cell lung cancer whose tumors had a specific gene change (EGFR mutation) but not another (T790M), and whose cancer had stopped responding to standard targeted therapy. Th…

This study tested a new insulin (22011) to see if it works as well as an existing insulin (Ryzodeg) for people with type 2 diabetes. 414 Chinese adults took part. The goal was to compare blood sugar control and safety. Results suggest the new insulin is a similar option for manag…

This early-stage study tested a new diabetes drug called rongliflozin in 32 people with type 2 diabetes who had normal or mildly to moderately reduced kidney function. The goal was to see how the drug moves through the body and how it affects blood sugar control. Participants too…

This early-stage trial tested a new medicine called HEC93077 in 126 healthy Chinese volunteers and people with high uric acid (gout). The main goals were to check safety, how the drug moves through the body, and how it affects uric acid levels. Participants received either the dr…

This early-stage study tested a new insomnia drug called HEC83518 in 74 healthy Chinese adults aged 18-45. The main goal was to check safety and side effects, not to measure how well it works. Researchers gave single rising doses to see how the body processes the drug.

This early-stage study tested a new insomnia medication called HEC83518 in 57 healthy Chinese adults aged 18 to 45. The main goal was to check if the drug is safe and how the body processes it, including the effect of food. Participants took multiple doses and were monitored for …

This study looked at how the diabetes drug rongliflozin is processed in people with mild or moderate liver damage compared to healthy people. 32 adults took a single dose of the drug, and researchers measured drug levels in the blood and checked for side effects. The goal was to …

This study looked at how the experimental drug clifutinib moves through and leaves the bodies of 6 healthy men. Participants took a single radioactive dose so researchers could track the drug in blood, urine, and stool. The goal was to understand how the drug is broken down and e…